Reports that Incyte Pharmaceuticals Inc. and SmithKline Beecham (SKB) are creating a joint venture company called diaDexus. Goal of diaDexus to discover and commercialize molecular diagnostic products; Use of bioformatics and genomics to develop tests for disease detection; How both companies bring significant technology and financial resources into the deal; Plans for diaDexus to license proprietary diagnostic markers to diagnostic-kit manufacturers.